Gene: EGFR ×
Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519847
rs1057519847
EGFR
0.020 GeneticVariation BEFREE No significant difference on PFS and OS was observed between exon 19 deletion and L858R mutation group for patients with bone metastasis. 28367239

2017
dbSNP: rs1057519848
rs1057519848
EGFR
0.020 GeneticVariation BEFREE No significant difference on PFS and OS was observed between exon 19 deletion and L858R mutation group for patients with bone metastasis. 28367239

2017
dbSNP: rs121434568
rs121434568
EGFR
0.020 GeneticVariation BEFREE No significant difference on PFS and OS was observed between exon 19 deletion and L858R mutation group for patients with bone metastasis. 28367239

2017
dbSNP: rs1057519847
rs1057519847
EGFR
0.020 GeneticVariation BEFREE She was being treated with gefitinib for lung adenocarcinoma positive for the epidermal growth factor receptor (EGFR) mutation L858R, and had multiple bone metastases. 26045851

2015
dbSNP: rs1057519848
rs1057519848
EGFR
0.020 GeneticVariation BEFREE She was being treated with gefitinib for lung adenocarcinoma positive for the epidermal growth factor receptor (EGFR) mutation L858R, and had multiple bone metastases. 26045851

2015
dbSNP: rs121434568
rs121434568
EGFR
0.020 GeneticVariation BEFREE She was being treated with gefitinib for lung adenocarcinoma positive for the epidermal growth factor receptor (EGFR) mutation L858R, and had multiple bone metastases. 26045851

2015
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.010 GeneticVariation BEFREE Plasma T790M status correlated with a higher number of metastatic sites (4 vs. 3, <i>p</i> < .001) and bone metastases (<i>p</i> = .0002).<b>Conclusion:</b> Plasma <i>EGFR</i> T790M testing had shorter TAT compared to tissue testing, however, it was longer than anticipated. 31347936

2019